In contrast to CWR22 tumours, LNCaP cells experienced increase in EGFR upon lapatinib treatment, likely reflecting variability of response of various HSPC models; whereas the response of CRPC models to lapatinib showing HER2 but not EGFR increase was consistent in all models used. Here, ERBB2 is linked to neoplasm.